JP2011526924A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011526924A5 JP2011526924A5 JP2011516857A JP2011516857A JP2011526924A5 JP 2011526924 A5 JP2011526924 A5 JP 2011526924A5 JP 2011516857 A JP2011516857 A JP 2011516857A JP 2011516857 A JP2011516857 A JP 2011516857A JP 2011526924 A5 JP2011526924 A5 JP 2011526924A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- mammal
- pharmaceutical composition
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- HDCSOVJJTFUIBB-UHFFFAOYSA-N CNOCCCO Chemical compound CNOCCCO HDCSOVJJTFUIBB-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7743208P | 2008-07-01 | 2008-07-01 | |
| US61/077,432 | 2008-07-01 | ||
| PCT/US2009/049449 WO2010003022A1 (en) | 2008-07-01 | 2009-07-01 | Isoindolone derivatives as mek kinase inhibitors and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011526924A JP2011526924A (ja) | 2011-10-20 |
| JP2011526924A5 true JP2011526924A5 (enExample) | 2012-08-16 |
| JP5615274B2 JP5615274B2 (ja) | 2014-10-29 |
Family
ID=41128054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011516857A Expired - Fee Related JP5615274B2 (ja) | 2008-07-01 | 2009-07-01 | Ｍｅｋキナーゼインヒビターとしてのイソインドロン誘導体及びその使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8492427B2 (enExample) |
| EP (1) | EP2307364B1 (enExample) |
| JP (1) | JP5615274B2 (enExample) |
| KR (1) | KR20110028376A (enExample) |
| CN (1) | CN102137843A (enExample) |
| AU (1) | AU2009266953A1 (enExample) |
| BR (1) | BRPI0910200A2 (enExample) |
| CA (1) | CA2727252A1 (enExample) |
| CL (1) | CL2010001637A1 (enExample) |
| ES (1) | ES2426096T3 (enExample) |
| IL (1) | IL209892A0 (enExample) |
| MX (1) | MX2010014565A (enExample) |
| PE (1) | PE20110424A1 (enExample) |
| RU (1) | RU2495028C2 (enExample) |
| WO (1) | WO2010003022A1 (enExample) |
| ZA (1) | ZA201008962B (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2598661B1 (en) | 2010-07-26 | 2017-09-27 | Biomatrica, INC. | Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
| US9376709B2 (en) | 2010-07-26 | 2016-06-28 | Biomatrica, Inc. | Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures |
| CN102020651B (zh) | 2010-11-02 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 6-芳基氨基吡啶酮甲酰胺mek抑制剂 |
| WO2014071183A1 (en) | 2012-11-02 | 2014-05-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor |
| US9725703B2 (en) | 2012-12-20 | 2017-08-08 | Biomatrica, Inc. | Formulations and methods for stabilizing PCR reagents |
| US20160135446A1 (en) | 2013-06-13 | 2016-05-19 | Biomatrica, Inc. | Cell stabilization |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| EP3061747B1 (en) | 2013-10-25 | 2021-04-07 | Shanghai Hengrui Pharmaceutical Co. Ltd. | Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof |
| DK3102576T3 (da) | 2014-02-03 | 2019-07-22 | Vitae Pharmaceuticals Llc | Dihydropyrrolopyridininhibitorer af ror-gamma |
| CN103922992B (zh) * | 2014-04-25 | 2015-09-02 | 温州大学 | 一种抗癌活性吲哚酮衍生物、合成方法及其用途 |
| WO2015191632A1 (en) | 2014-06-10 | 2015-12-17 | Biomatrica, Inc. | Stabilization of thrombocytes at ambient temperatures |
| US20170114323A1 (en) | 2014-06-19 | 2017-04-27 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| SI3207043T1 (sl) | 2014-10-14 | 2019-04-30 | Vitae Pharmaceuticals, Inc. | Dihidropirolopiridinovi inhibitorji za ROR-gama |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| CN104860869B (zh) * | 2015-04-03 | 2017-11-03 | 北京大学 | 具有mek激酶抑制功能的化合物及其制备方法与应用 |
| MA42145B1 (fr) | 2015-05-20 | 2020-05-29 | Amgen Inc | Triazoles agonistes du récepteur apj |
| EP3331876B1 (en) | 2015-08-05 | 2020-10-07 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
| US20190008859A1 (en) | 2015-08-21 | 2019-01-10 | Acerta Pharma B.V. | Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor |
| EP3868750A1 (en) | 2015-11-20 | 2021-08-25 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
| ES2946184T3 (es) | 2015-12-08 | 2023-07-13 | Biomatrica Inc | Reducción de la velocidad de eritrosedimentación |
| TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| AU2017249229A1 (en) | 2016-04-15 | 2018-10-04 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| EP3452466B1 (en) | 2016-05-03 | 2020-08-12 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
| US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| EP3541802B1 (en) | 2016-11-16 | 2025-01-01 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the apj receptor |
| EP3541792B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
| US11046680B1 (en) | 2016-11-16 | 2021-06-29 | Amgen Inc. | Heteroaryl-substituted triazoles as APJ receptor agonists |
| US10906890B2 (en) | 2016-11-16 | 2021-02-02 | Amgen Inc. | Triazole phenyl compounds as agonists of the APJ receptor |
| EP3541803B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
| WO2018093577A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the apj receptor |
| RU2742234C1 (ru) | 2017-06-23 | 2021-02-03 | Систоун Фармасьютикалс | Кумариноподобное циклическое соединение в качестве ингибитора мек и его применение |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| CN115716826A (zh) | 2017-07-24 | 2023-02-28 | 生命医药有限责任公司 | RORγ的抑制剂 |
| KR102811888B1 (ko) | 2017-09-08 | 2025-05-27 | 에프. 호프만-라 로슈 아게 | 암의 진단 및 치료 방법 |
| WO2019089335A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | Fused triazole agonists of the apj receptor |
| US11434249B1 (en) | 2018-01-02 | 2022-09-06 | Seal Rock Therapeutics, Inc. | ASK1 inhibitor compounds and uses thereof |
| US20210008047A1 (en) | 2018-02-13 | 2021-01-14 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| EP3788037A1 (en) | 2018-05-01 | 2021-03-10 | Amgen Inc. | Substituted pyrimidinones as agonists of the apj receptor |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| JP2024521788A (ja) | 2021-05-27 | 2024-06-04 | ミラティ セラピューティクス， インコーポレイテッド | 併用療法 |
| CN118973580A (zh) | 2022-04-08 | 2024-11-15 | 米拉蒂治疗股份有限公司 | 包含sos1抑制剂和mek抑制剂的组合疗法 |
| US20260048075A1 (en) | 2022-08-10 | 2026-02-19 | Vib Vzw | Inhibition of TCF4/ITF2 in the Treatment of Cancer |
| WO2026019990A1 (en) | 2024-07-18 | 2026-01-22 | Genentech, Inc. | Methods of treating cancer with anti-ccr8/anti-cd3 bispecific antibodies |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA711710B (en) | 1970-05-28 | 1971-12-29 | Squibb & Sons Inc | Amino derivatives of purazolo-pyridine carboxylic acids and esters |
| US3736326A (en) | 1971-03-29 | 1973-05-29 | Squibb & Sons Inc | Isoxazolopyridine carboxylic acids and esters |
| US4012373A (en) | 1972-09-22 | 1977-03-15 | E. R. Squibb & Sons, Inc. | Pyrazolo[3',4'-2,3]pyrido[4,5-e]b-benzo-1,5-diazepinones |
| GB8404586D0 (en) | 1984-02-22 | 1984-03-28 | Beecham Group Plc | Compounds |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| IL147150A0 (en) | 1999-07-16 | 2002-08-14 | Warner Lambert Co | Method for treating chronic pain using mek inhibitors |
| JP2002020386A (ja) | 2000-07-07 | 2002-01-23 | Ono Pharmaceut Co Ltd | ピラゾロピリジン誘導体 |
| AU7349801A (en) | 2000-07-19 | 2002-01-30 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| SG2013013339A (en) * | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| WO2003077855A2 (en) * | 2002-03-13 | 2003-09-25 | Array Biopharma, Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| GB0316237D0 (en) | 2003-07-11 | 2003-08-13 | Astrazeneca Ab | Therapeutic agents |
| GB0316232D0 (en) | 2003-07-11 | 2003-08-13 | Astrazeneca Ab | Therapeutic agents |
| US20050049276A1 (en) | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
| CA2532067C (en) * | 2003-07-24 | 2010-12-21 | Stephen Douglas Barrett | N-methyle-substituted benzamidazoles |
| DK1663242T3 (da) | 2003-08-07 | 2011-08-01 | Rigel Pharmaceuticals Inc | 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler |
| US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| KR101190912B1 (ko) * | 2003-11-19 | 2012-10-12 | 어레이 바이오파마 인크. | Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법 |
| WO2005054176A1 (en) | 2003-11-25 | 2005-06-16 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
| KR20060127886A (ko) | 2003-12-19 | 2006-12-13 | 바이오비트럼 에이비 | 5-ｈｔ6 수용체-관련 장애의 예방 및 치료에 사용될 수있는, 신규한 벤조퓨란 유도체 |
| CN101061101B (zh) | 2003-12-22 | 2011-09-07 | 巴斯利尔药物股份公司 | 芳酰基呋喃和芳酰基噻吩 |
| EP1699488A2 (en) | 2003-12-23 | 2006-09-13 | Pfizer Products Incorporated | Therapeutic combination for cognition enhancement and psychotic disorders |
| AU2006284751A1 (en) | 2005-09-01 | 2007-03-08 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| NZ567140A (en) | 2005-10-07 | 2011-09-30 | Exelixis Inc | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
| WO2008028141A2 (en) | 2006-08-31 | 2008-03-06 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
-
2009
- 2009-07-01 JP JP2011516857A patent/JP5615274B2/ja not_active Expired - Fee Related
- 2009-07-01 CN CN2009801337804A patent/CN102137843A/zh active Pending
- 2009-07-01 RU RU2011103434/04A patent/RU2495028C2/ru not_active IP Right Cessation
- 2009-07-01 CA CA2727252A patent/CA2727252A1/en not_active Abandoned
- 2009-07-01 EP EP09774472.6A patent/EP2307364B1/en active Active
- 2009-07-01 AU AU2009266953A patent/AU2009266953A1/en not_active Abandoned
- 2009-07-01 WO PCT/US2009/049449 patent/WO2010003022A1/en not_active Ceased
- 2009-07-01 MX MX2010014565A patent/MX2010014565A/es active IP Right Grant
- 2009-07-01 ES ES09774472T patent/ES2426096T3/es active Active
- 2009-07-01 BR BRPI0910200A patent/BRPI0910200A2/pt not_active IP Right Cessation
- 2009-07-01 KR KR1020117002455A patent/KR20110028376A/ko not_active Ceased
- 2009-07-01 US US12/998,000 patent/US8492427B2/en not_active Expired - Fee Related
- 2009-07-01 PE PE2010001200A patent/PE20110424A1/es not_active Application Discontinuation
-
2010
- 2010-12-09 IL IL209892A patent/IL209892A0/en unknown
- 2010-12-13 ZA ZA2010/08962A patent/ZA201008962B/en unknown
- 2010-12-30 CL CL2010001637A patent/CL2010001637A1/es unknown